Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment
- PMID: 15037110
- DOI: 10.1016/j.exer.2003.11.016
Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment
Abstract
This review summarizes the Ernst H. Bárány Prize Lecture given at the meeting of the International Society of Eye Research in Geneva 2002. In the paper the path from the author's early studies on neurogenic inflammation in the eye to the search for a suitable prostaglandin analogue for glaucoma treatment, and the development of latanoprost are described. In particular the solution to the nociceptive and hyperemic side-effects of naturally occurring prostaglandins in the eye, the mechanism of action of FP prostanoid receptor agonists as well as the selection of dose for glaucoma treatment are discussed. In addition, pharmacokinetical aspects of latanoprost, and the melanogenic side-effect of prostaglandins in the iris are addressed. The paper is primarily focused on studies performed by the author and complete reference to other previous, or contemporary studies is therefore not always given as the purpose is not to present a comprehensive review article.
Similar articles
-
Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.Exp Eye Res. 2004 Apr;78(4):767-76. doi: 10.1016/j.exer.2003.12.007. Exp Eye Res. 2004. PMID: 15037111
-
Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.Prog Retin Eye Res. 2000 Jul;19(4):459-96. doi: 10.1016/s1350-9462(00)00003-3. Prog Retin Eye Res. 2000. PMID: 10785618 Review.
-
Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment.Adv Prostaglandin Thromboxane Leukot Res. 1995;23:63-8. Adv Prostaglandin Thromboxane Leukot Res. 1995. PMID: 7732906 Review. No abstract available.
-
A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.Jpn J Ophthalmol. 2004 Mar-Apr;48(2):141-7. doi: 10.1007/s10384-003-0039-6. Jpn J Ophthalmol. 2004. PMID: 15060793
-
Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect.Surv Ophthalmol. 1997 Feb;41 Suppl 2:S1-14. doi: 10.1016/s0039-6257(97)80002-1. Surv Ophthalmol. 1997. PMID: 9154271 Review.
Cited by
-
Prostanoid receptor agonists for glaucoma treatment.Jpn J Ophthalmol. 2021 Sep;65(5):581-590. doi: 10.1007/s10384-021-00844-6. Epub 2021 Jul 6. Jpn J Ophthalmol. 2021. PMID: 34228229 Review.
-
Regulation of prostaglandin EP1 and EP4 receptor signaling by carrier-mediated ligand reuptake.Pharmacol Res Perspect. 2014 Oct;2(5):e00051. doi: 10.1002/prp2.51. Epub 2014 Jul 4. Pharmacol Res Perspect. 2014. PMID: 25505603 Free PMC article.
-
Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.Clin Ophthalmol. 2010 Jul 30;4:741-64. doi: 10.2147/opth.s10441. Clin Ophthalmol. 2010. PMID: 20689791 Free PMC article.
-
Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.ACS Pharmacol Transl Sci. 2020 Nov 5;3(6):1391-1421. doi: 10.1021/acsptsci.0c00137. eCollection 2020 Dec 11. ACS Pharmacol Transl Sci. 2020. PMID: 33344909 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical